Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Drop in Short Interest

Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 208,100 shares, a decline of 24.3% from the November 15th total of 274,900 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily volume of 261,300 shares, the short-interest ratio is presently 0.8 days.

Tiziana Life Sciences Stock Performance

Shares of TLSA stock remained flat at $0.94 during mid-day trading on Friday. 42,886 shares of the stock traded hands, compared to its average volume of 214,376. Tiziana Life Sciences has a one year low of $0.41 and a one year high of $1.74. The company has a fifty day simple moving average of $0.95 and a 200-day simple moving average of $0.97.

Hedge Funds Weigh In On Tiziana Life Sciences

A hedge fund recently raised its stake in Tiziana Life Sciences stock. Zhang Financial LLC boosted its holdings in Tiziana Life Sciences Ltd (NASDAQ:TLSA - Free Report) by 24.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,387 shares of the company's stock after purchasing an additional 13,500 shares during the quarter. Zhang Financial LLC owned approximately 0.07% of Tiziana Life Sciences worth $67,000 as of its most recent filing with the Securities and Exchange Commission.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.